BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 137 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 0.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $544 | +23.9% | 76,896 | +23.2% | 0.00% | 0.0% |
| Q2 2023 | $439 | -74.6% | 62,398 | -69.9% | 0.00% | -50.0% |
| Q1 2023 | $1,727 | -38.1% | 207,093 | -14.8% | 0.00% | -50.0% |
| Q4 2022 | $2,789 | -99.9% | 242,965 | +3.8% | 0.00% | 0.0% |
| Q3 2022 | $2,950,000 | +18.2% | 234,165 | -0.8% | 0.00% | +33.3% |
| Q2 2022 | $2,496,000 | -61.9% | 235,962 | -41.5% | 0.00% | -57.1% |
| Q1 2022 | $6,556,000 | +142.7% | 403,195 | +106.8% | 0.01% | +133.3% |
| Q4 2021 | $2,701,000 | +11.3% | 194,995 | +15.5% | 0.00% | 0.0% |
| Q3 2021 | $2,426,000 | -23.6% | 168,853 | -15.9% | 0.00% | 0.0% |
| Q2 2021 | $3,176,000 | +47.3% | 200,857 | -5.2% | 0.00% | +50.0% |
| Q1 2021 | $2,156,000 | +94.2% | 211,950 | +42.2% | 0.00% | +100.0% |
| Q4 2020 | $1,110,000 | +142.9% | 149,000 | +11.9% | 0.00% | 0.0% |
| Q3 2020 | $457,000 | -27.9% | 133,100 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $634,000 | +138.3% | 133,100 | 0.0% | 0.00% | – |
| Q1 2020 | $266,000 | -42.0% | 133,100 | 0.0% | 0.00% | -100.0% |
| Q4 2019 | $459,000 | +57.2% | 133,100 | +30.7% | 0.00% | – |
| Q3 2019 | $292,000 | -24.4% | 101,800 | 0.0% | 0.00% | – |
| Q2 2019 | $386,000 | -53.4% | 101,800 | 0.0% | 0.00% | -100.0% |
| Q1 2019 | $829,000 | +0.9% | 101,800 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $822,000 | +5.8% | 101,800 | 0.0% | 0.00% | 0.0% |
| Q3 2018 | $777,000 | +33.3% | 101,800 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $583,000 | +20.0% | 101,800 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $486,000 | -2.8% | 101,800 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $500,000 | +13.9% | 101,800 | +21.5% | 0.00% | 0.0% |
| Q3 2017 | $439,000 | -5.8% | 83,800 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $466,000 | -19.9% | 83,800 | +20.9% | 0.00% | 0.0% |
| Q1 2017 | $582,000 | +32.6% | 69,301 | +0.0% | 0.00% | 0.0% |
| Q4 2016 | $439,000 | +43.5% | 69,300 | 0.0% | 0.00% | – |
| Q3 2016 | $306,000 | +55.3% | 69,300 | 0.0% | 0.00% | – |
| Q2 2016 | $197,000 | +0.5% | 69,300 | 0.0% | 0.00% | – |
| Q1 2016 | $196,000 | -72.6% | 69,300 | 0.0% | 0.00% | -100.0% |
| Q4 2015 | $715,000 | -9.5% | 69,300 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $790,000 | -29.0% | 69,300 | -7.0% | 0.00% | -50.0% |
| Q2 2015 | $1,112,000 | – | 74,497 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 7,637,700 | $77,675,000 | 7.44% |
| Burrage Capital Management LLC | 864,916 | $8,796,000 | 7.13% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,367,670 | $24,079,000 | 3.61% |
| HealthCor Management, L.P. | 4,886,440 | $49,695,000 | 1.76% |
| Ghost Tree Capital, LLC | 500,000 | $5,085,000 | 1.20% |
| Integral Health Asset Management, LLC | 400,000 | $4,068,000 | 1.16% |
| Lisanti Capital Growth, LLC | 472,520 | $4,806,000 | 0.62% |
| Parkman Healthcare Partners LLC | 244,680 | $2,488,000 | 0.58% |
| Baker Brothers Advisors | 12,710,818 | $129,269,000 | 0.56% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,605,380 | $26,497,000 | 0.56% |